Abstract
Depression is a major albeit neglected complication in patients with traumatic brain injury (TBI). Elucidating its neural correlates remains an important milestone with respect to understanding the disorder and helping with the rehabilitation process. Towards this direction, neuropsychological theories have proposed abnormal brain dynamics as the neural basis of depressive symptomatology. This observational study addressed the question of whether depression in TBI patients is related to abnormal brain dynamics using a sample of 81 TBI patients with depressive symptomatology. To explore brain dynamics we employed the Hidden Markov model that utilises resting-state fMRI data to identify the states that the brain visits sequentially during scanning. Spatial (highest activated regions) and temporal (occupancy, switching rate) characteristics of these states were used to analyse the networks involved and probe differences between depressed and non-depressed TBI patients. We found a significant positive association between depression score and the fractional occupancy and switching rate of two specific states that distinguished between depressed and non-depressed TBI patients. These states spanned default mode, subcortical and cerebellar regions while also forming a temporally coherent “metastate” that the depressed brain would recurrently visit. Depression in TBI patients is characterised by abnormal recruitment and repetitive sequencing between certain neural networks. These results point to the existence of a reinforced, self-referential circuitry that could provide the basis for targeted therapies during the recovery process.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study involved secondary analysis of data collected by other studies, including the MRC collaborative Grant and TBICare. L.M.L. was funded by Addenbrooke's Charitable Trust (ACT) Grant 900089. A.M. is supported by CLAHRC-East of England awards. E.L.C., J.G.O., J.P.C. and D.K.M. are funded by the Neuroscience Theme of the NIHR Cambridge Biomedical Research Centre and NIHR and by Framework Program 7 funding from the European Commission (CENTER-TBI). E.A.S. is funded by the Stephen Erskine Fellowship, Queens College, Cambridge, UK. V.F.J.N. is supported by a Health Foundation/Academy of Medical Sciences Clinician Scientist Fellowship. BJS receives funding from the NIHR MedTech and in vitro Diagnostic Co-operative and the NIHR Cambridge Biomedical Research Centre (BRC) (Mental Health Theme).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Cambridgeshire Research Ethics Committee (Cambridge local Ethics committee reference number of approval LREC 97/290).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data and materials can be provided upon reasonable request to the authors
